Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomized Clinical Trial for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant (FMT) in Stage II-III Non-small Cell Lung Cancer (NSCLC) Patients, Using Immune Checkpoint Inhibitors (ICI) Responders as Donors.

NCT07247786 is registered in ClinicalTrials.gov with Fundación GECP as lead sponsor.

NCT NCT07247786
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07247786 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomized Clinical Trial for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant (FMT) in Stage II-III Non-small Cell Lung Cancer (NSCLC) Patients, Using Immune Checkpoint Inhibitors (ICI) Responders as Donors.
Lead sponsor
Fundación GECP
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 15, 2026
Completion date
December 30, 2031
Enrollment
68 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer, respiratory tract neoplasm